文献速递艾滋病与性传播感染

整合酶抑制剂方案间歇短周期维持治疗HIV病毒学抑制患者有效

Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

这项队列研究纳入73例病毒学抑制的HIV成人患者,换用基于整合酶抑制剂的每周4天或5天服药方案。48周病毒学有效率100%,96周为93.7%,提示间歇维持治疗在真实世界中有效。

要点

  • 基于INSTI的每周4天或5天服药方案在48周病毒学有效率达100%
  • 96周病毒学有效率93.7%,2例病毒学失败发生在60周和67周
  • 间歇维持方案在真实世界中对INSTI方案与PI/NNRTI方案同样有效

核心结论

  • 基于整合酶抑制剂的间歇维持三药方案(每周休息2或3天)在病毒学抑制的HIV患者中显示良好病毒学疗效。

研究设计与样本

  • 队列研究,纳入73例接受ART且病毒载量<50 copies/mL超过1年的成人患者,换用基于INSTI的三药方案每周4天或5天给药。

主要发现

  • 共73例患者(4天组28例,5天组45例),中位随访21个月,总随访161患者年。
  • 48周病毒学成功率100%(95%CI 94%-100%),96周为93.7%(95%CI 79.8%-98.2%)。
  • 4例停止策略:2例病毒学失败(第60周和第67周),1例因肾毒性换药(第28周),1例换用利匹韦林/多替拉韦(第65周)。

关键数值与推荐

  • 病毒学失败定义为确认VL≥50 copies/mL。
  • 基线中位年龄51岁(IQR 45-57),ART duration 10年(IQR 6-18),病毒抑制 duration 5年(IQR 2-9)。

临床怎么用

  • 对于经选择的病毒学抑制HIV患者,可考虑基于INSTI的每周4天或5天间歇维持治疗,但需密切监测病毒载量。

局限性

  • 样本量小(73例),非随机设计,随访时间有限(中位21个月),需等待大型随机QUATUOR ANRS-170研究最终结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have shown that NNRTI/PI-based triple therapy could be safely administered as a 4 days (4D) or 5 days (5D) a week maintenance strategy. We report here our experience of using an integrase inhibitor (INSTI)-based 4D/5D regimen in virologically suppressed HIV patients. METHODS: This cohort study enrolled adult patients on ART with viral load (VL) <50 copies/mL for >1 year, who switched to an INSTI-based triple regimen given 4D/5D a week. The primary endpoint was the virological efficacy rate at Week (W) 48, with virological failure defined as confirmed VL ≥50 copies/mL. RESULTS: A total of 73 patients were included (n = 28 for 4D, n = 45 for 5D): 54 men (74%), median (IQR) age 51 (45-57) years, ART duration 10 (6-18) years and duration of viral suppression 5 (2-9) years at baseline. As of 25 March 2019, the median follow-up was 21 (14-35) months, with a total of 161 patient-years of follow-up; all patients had reached the W24 visit, 66 (90%) W48 and 34 (47%) W96. Four patients discontinued the strategy: virological failure (n = 2) at W60 and W67, respectively, switch for renal toxicity (n = 1) at W28 and switch to rilpivirine/dolutegravir (n = 1) at W65. Overall the rate of virological success (95% CI) was 100% (94%-100%) at W24 and W48 and 93.7% (79.8%-98.2%) at W96. CONCLUSIONS: While waiting for the final results of the large randomized QUATUOR ANRS-170 study, our real-life results suggest that the use of an intermittent maintenance triple-drug regimen given as a weekend (2 or 3 days) off is as effective with an INSTI-based regimen as with a PI or an NNRTI.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Calin R, Landowski S, Valantin MA, et al. Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients. J Antimicrob Chemother. 2020. PMID: 31977046. doi:10.1093/jac/dkz555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。